Actos (Pioglitazone) Cost in Arizona 2026: Prices, Insurance, and Savings

What Does Generic Pioglitazone Cost at Arizona Pharmacies?

Generic pioglitazone is one of the least expensive branded-to-generic diabetes drugs on the market in 2026. Arizona residents paying out of pocket can expect to spend roughly $15 per month for a 30-day supply of generic pioglitazone at most chain and independent pharmacies across the state.

That figure reflects the statewide retail average. Prices can shift by a few dollars depending on the pharmacy chain, your location within Arizona, and the specific dosage strength prescribed. A 15 mg tablet may cost slightly less than the 45 mg tablet at certain pharmacies, though the gap is usually small. Costco, Walmart, and several grocery-chain pharmacies in the Phoenix and Tucson metro areas tend to post prices at or below the $15 average for 30 tablets.

The branded version, Actos, manufactured by Takeda, carries a list price of approximately $60 per month. Because pioglitazone lost patent exclusivity years ago, very few patients pay for the brand name unless their insurance formulary specifically requires it. The FDA-approved label for pioglitazone lists type 2 diabetes mellitus as the primary indication, with dosing at 15 mg to 45 mg once daily.

For context, pioglitazone belongs to the thiazolidinedione (TZD) class. It works by activating peroxisome proliferator-activated receptor gamma (PPAR-gamma), which improves insulin sensitivity in muscle and adipose tissue. A 2010 PIVENS trial published in the New England Journal of Medicine (N=247) demonstrated that pioglitazone 30 mg daily produced significant histological improvement in nonalcoholic steatohepatitis (NASH) compared to placebo, with 34% of pioglitazone-treated patients achieving the primary endpoint versus 19% on placebo (P=0.04). This trial remains a reference point for off-label prescribing.

Does Arizona Medicaid (AHCCCS) Cover Pioglitazone?

No. Arizona's Medicaid program, known as AHCCCS (Arizona Health Care Cost Containment System), does not currently include pioglitazone on its preferred drug list as of 2026.

This means AHCCCS enrollees who need pioglitazone will either need to pursue a prior authorization exception, switch to a formulary-covered alternative like metformin or a sulfonylurea, or pay cash out of pocket. Prior authorization requests for non-formulary drugs through AHCCCS require documentation from the prescribing clinician showing medical necessity, such as documented failure or intolerance to at least one preferred agent.

The practical effect of this coverage gap is less severe than it might seem at first, given the low cash price. At $15 per month, pioglitazone costs less than many insured copays for preferred brand-name medications. Still, for patients managing multiple prescriptions on a limited income, even $15 adds up. The American Diabetes Association Standards of Care recommend thiazolidinediones as a second- or third-line option when metformin alone does not achieve glycemic targets, particularly when insulin sensitization is the clinical priority.

Arizona patients enrolled in Medicare Part D may find pioglitazone covered under most formularies, typically at Tier 1 or Tier 2 generic pricing. A Medicare Part D copay for pioglitazone usually falls between $0 and $10 depending on the plan, making it cheaper through insurance than cash pay in many cases.

Which Insurance Plans Cover Pioglitazone in Arizona?

Most commercial insurance plans sold in Arizona include generic pioglitazone on their formularies. Because the drug is inexpensive and widely prescribed, major insurers such as Blue Cross Blue Shield of Arizona, UnitedHealthcare, Cigna, Aetna, and Banner/Aetna plans typically place it on Tier 1 (preferred generic).

Tier 1 placement generally means a copay between $0 and $15, depending on the specific plan design. Some high-deductible health plans (HDHPs) paired with health savings accounts may require the patient to meet the deductible first, but even then the negotiated rate for generic pioglitazone is usually close to the $15 retail average.

For patients on employer-sponsored insurance, checking the plan's formulary lookup tool online or calling the pharmacy benefit manager (PBM) directly is the fastest way to confirm coverage. Express Scripts, CVS Caremark, and OptumRx all list pioglitazone as a covered generic in their standard 2026 formularies.

Arizona Health Insurance Marketplace (ACA) plans are required to cover at least one drug in each pharmacological class. Since metformin fills the biguanide slot and pioglitazone fills the thiazolidinedione slot, most Marketplace plans include pioglitazone. The Endocrine Society Clinical Practice Guidelines note that TZDs remain appropriate for patients with specific contraindications to other glucose-lowering agents, supporting formulary inclusion arguments when needed.

A 2022 analysis in Diabetes Care found that TZD prescribing declined by 47% between 2012 and 2020, largely due to safety concerns around fluid retention and fracture risk, but that prescribing stabilized after 2020 as clinicians recognized the drug's benefits in NASH and insulin-resistant phenotypes (Diabetes Care, 2022).

Is Compounded Pioglitazone Legal in Arizona?

Yes. Licensed 503A compounding pharmacies in Arizona can legally compound pioglitazone for individual patients with a valid prescription. Arizona follows federal guidelines established under Section 503A of the Federal Food, Drug, and Cosmetic Act, which permits patient-specific compounding when a prescriber determines a clinical need.

Compounding might be relevant for patients who need a dose not commercially available, require a liquid suspension instead of a tablet, or have allergies to inactive ingredients in the manufactured product. The cost for compounded pioglitazone in Arizona can be as low as $0 at certain pharmacies that bundle compounding fees into dispensing, though most charge a small preparation fee.

The FDA's guidance on 503A compounding requires that the compounded drug not be a copy of a commercially available product in the same strength and dosage form, unless the prescriber documents a clinical difference for the individual patient. Arizona's Board of Pharmacy enforces these rules at the state level.

One important distinction: 503B outsourcing facilities operate under different rules and can produce compounded medications in larger batches without patient-specific prescriptions, but pioglitazone is rarely compounded through 503B facilities because the generic tablet is already inexpensive and widely available. For most Arizona patients, buying the generic tablet will be simpler and cheaper than seeking a compounded version.

How to Get the Lowest Price for Pioglitazone in Arizona

Several strategies can push the cost of pioglitazone below the $15 monthly average.

GoodRx and similar discount cards. Free prescription discount platforms like GoodRx, RxSaver, and SingleCare often show prices between $4 and $12 for a 30-day supply of pioglitazone 15 mg or 30 mg at Arizona pharmacies. Walmart and Costco pharmacies (Costco does not require a membership for pharmacy purchases) frequently appear as the lowest-cost options on these platforms.

Manufacturer savings programs. Takeda, the manufacturer of branded Actos, has periodically offered savings cards, though these apply only to the brand-name product. For patients prescribed generic pioglitazone, manufacturer cards are not applicable. Generic manufacturers do not typically offer patient savings programs because the price is already low.

$4 generic lists. Several national pharmacy chains include pioglitazone on their $4 generic programs for a 30-day supply. In Arizona, Walmart's $4 list and Kroger-affiliated Fry's Food pharmacy $4 program both include pioglitazone. This is the cheapest option for uninsured patients.

Patient assistance programs. Takeda offers a patient assistance program (TAP) for qualifying low-income patients prescribed branded Actos, but eligibility is limited to patients without insurance who meet income thresholds. For most Arizona patients, the generic at $4 to $15 makes applying for assistance programs unnecessary.

A 2021 study in the Annals of Internal Medicine examining out-of-pocket costs for diabetes medications found that TZDs had the lowest median monthly cost among all oral diabetes drug classes at $9, compared to $30 for SGLT2 inhibitors and $850 for branded GLP-1 receptor agonists. This price advantage makes pioglitazone one of the most accessible diabetes medications in Arizona and nationally.

Can You Get Pioglitazone via Telehealth in Arizona?

Yes. Arizona permits telehealth prescribing of pioglitazone without restriction. A clinician licensed in Arizona can evaluate a patient via video or audio visit and prescribe pioglitazone if clinically indicated. Arizona's telehealth parity laws, updated in 2021, treat telehealth visits equivalently to in-person visits for prescribing purposes.

Pioglitazone is not a controlled substance, so it does not face the additional telehealth prescribing barriers that apply to Schedule II through V drugs. Any Arizona-licensed physician, nurse practitioner, or physician assistant can prescribe it after an appropriate clinical evaluation.

Several telehealth platforms operating in Arizona offer diabetes management services that include prescribing pioglitazone. Patients in rural parts of the state, including areas of Mohave, Yuma, and Apache counties with limited endocrinology access, may find telehealth particularly useful. The American Association of Clinical Endocrinology (AACE) guidelines support telehealth-based diabetes management as equivalent to in-person care for stable patients on oral medications.

After receiving a prescription through telehealth, patients can fill it at any Arizona pharmacy, including mail-order pharmacies, which may offer additional savings on a 90-day supply. A 90-day supply through mail-order services like Amazon Pharmacy, Mark Cuban Cost Plus Drugs, or Costco mail order can reduce the per-month cost to $3 to $8.

Pioglitazone Safety Considerations That Affect Cost Decisions

Cost is only one factor in the decision to use pioglitazone. The drug carries specific risks that patients and prescribers must weigh.

The FDA requires a boxed warning on pioglitazone regarding the risk of congestive heart failure exacerbation. Patients with NYHA Class III or IV heart failure should not use pioglitazone. Fluid retention, peripheral edema, and weight gain of 2 to 4 kg are common side effects that occur in roughly 5% to 15% of patients, depending on dose and concomitant insulin use (FDA pioglitazone label).

Bone fracture risk is elevated with long-term TZD use, particularly in postmenopausal women. A meta-analysis published in the BMJ found that TZD use was associated with a 1.5-fold increased risk of fractures in women (95% CI 1.2 to 1.9), but not in men. Arizona clinicians should consider baseline bone density and fall risk before prescribing pioglitazone to older female patients.

Bladder cancer risk was a concern following early post-marketing data, but the 10-year follow-up of the Kaiser Permanente Northern California cohort published in JAMA Internal Medicine found no statistically significant increased risk of bladder cancer with pioglitazone use (HR 1.06 to 95% CI 0.89 to 1.26). The FDA updated its safety communication in 2016 to reflect this finding while maintaining the recommendation for periodic monitoring.

These safety factors do not directly change the drug's price, but they influence the total cost of therapy. A patient who develops edema may need a loop diuretic ($4 to $10 per month), and one who experiences a fracture faces costs that dwarf any savings on medication. The clinical decision, not the price tag, should drive prescribing.

Off-Label Use for NASH: Why Arizona Patients Ask About Pioglitazone

Pioglitazone has gained attention for its role in treating nonalcoholic steatohepatitis (NASH), now often called metabolic dysfunction-associated steatohepatitis (MASH). The PIVENS trial (N=247) showed that pioglitazone 30 mg daily improved steatohepatitis histology scores significantly, with 47% of pioglitazone patients showing improvement in steatosis grade versus 30% on placebo.

The AASLD Practice Guidance for NAFLD lists pioglitazone as a treatment option for biopsy-proven NASH in patients with or without type 2 diabetes. Dr. Arun Sanyal, who led the PIVENS trial, has noted that "pioglitazone remains the best-studied oral agent for NASH, with consistent histological benefits across multiple trials."

For Arizona patients prescribed pioglitazone off-label for NASH, insurance coverage can be more complicated. Insurers may require documentation of the off-label indication and supporting evidence before approving coverage. However, because the generic costs so little, many patients and prescribers bypass the prior authorization process entirely and pay cash. At $4 to $15 per month, pioglitazone is a fraction of the cost of newer NASH-targeted therapies like resmetirom (Rezdiffra), which can exceed $1,500 per month.

The 2024 AACE/AASLD joint statement recommends pioglitazone as a first-line pharmacotherapy option for NASH in patients with coexisting insulin resistance or type 2 diabetes, reinforcing its clinical relevance and supporting its use regardless of insurance coverage status.